Selective estrogen receptor modulators (SERMs) for uterine leiomyomas

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Wu, Taixiang ^a   Chen, X ^b   Xie, L ^b  

^a SICHUAN UNIVERSITY   (China)

^b NONE

Author keywords

Leiomyoma *drug therapy ; Leuprolide adverse effects; therapeutic use ; Raloxifene adverse effects; therapeutic use ; Randomized controlled trials as topic; Selective estrogen receptor modulators adverse effects; *therapeutic use

Indexed keywords

DANAZOL; ESTROGEN; HERBACEOUS AGENT; LEUPRORELIN; MIFEPRISTONE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MORTALITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNSPECIFIED SIDE EFFECT; UTERINE ARTERY EMBOLIZATION; UTERUS MYOMA; UTERUS SURGERY; FEMALE; LEIOMYOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); UTERINE NEOPLASMS;

FEMALE; HUMANS; LEIOMYOMA; LEUPROLIDE; RALOXIFENE HYDROCHLORIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UTERINE NEOPLASMS;

EID: 44949164746     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005287.pub3     Document Type: Review

References (39)

1. Jirecek 2004 {published data only} Jirecek S, Lee A, Pavo I, Crans G, Eppel W, Wenzl R. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertility and Sterility 2004;81(1):132-6. [MEDLINE: PUBMED 14711556].
2. Palomba 2002a {published data only} Palomba S, Russo T, Orio F Jr, Tauchmanova L, Zupi E, Panici PL, et al.Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Human Reproduction 2002;17(12):3213-9. [MEDLINE: PUBMED 12456626].
3. Palomba 2002b {published data only} *Palomba S, Orio F Jr, Morelli M, Russo T, Pellicano M, Zupi E, et al.Raloxifene Administration in Premenopausal Women with Uterine Leiomyomas: A Pilot Study. The Journal of Clinical Endocrinology & Metabolism 2002;87(8):3603-8. [MEDLINE: PUBMED 12161482].
4. Goldstein 2002 Goldstein-SR. Controversy about uterine effects and safety of SERMs: The saga continues. Menopause 2002;9(5):381-4.
5. Palomba 2001 Palomba S, Sammartino A, Di Carlo C, Affinito P, Zullo F, Nappi C. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertility and Sterility 2001;76(1):38-43.
6. Palomba 2002 Palomba S, Orio F Jr, Morelli M, Russo T, Pellicano M, Nappi C. Raloxifene administration in women treated with gonadotropin- releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. Journal of Clinical Endocrinology & Metabolism 2002; 87(10):4476-81.
7. Palomba 2004 Palomba S, Orio F Jr, Morelli M, Russo T, Pellicano M, Nappi C.. Raloxifene. Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene. Human Reproduction 2004;19(2):415-21.
8. Borgfeldt 2000 Borgfeldt C, Andolf E. Transvaginal ultrasonographic findings in the uterus and the endometrium: low prevalence of leiomyoma in a random sample of women age 25-40 years. Acta Obstetricia et Gynecologica Scandinavica 2000;79(3):202-7.
9. Boss 1997 Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhunt CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. American Journal of Obstetrics and Gynecology 1997;177:1458-64.
10. Buttram 1981 Buttram VC Jr, Reiter RC. Uterine leiomyomas: Etiology, symptamology, and management. Fertility and Sterility 1981;36:433-45.
11. Consort 2001 Moher, D, Schulz, K. F, Altman. D. G. The CONSORT statement. 2001.
12. Delmas 1997 Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al.Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. The New England Journal of Medicine 1997; 337:1641-7.
13. Draper 1996 Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. Journal of Bone and Mineral Research 1996;11:835-42.
14. Egger 1997 Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ Journals 1997;315:629-34.
15. Eli 1997 Indianapolis: Eli Lilly, Company. Raloxifene. Package insert 1997.
16. Ettingrr 1999 Ettingrr B. Black DM. Mitlak BH, et al.Recduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Journal of the American Medical Association 1999; 282:637-45.
17. Farber 1972 Farber M, Conrad S, Heinrichs NL, Herrman WL. Estradiol binding by fibroid tumors and normal myometrtium. Obstetrics and Gynecology 1972;40:479-83.
18. FIGO 2001 The International Federation of Gynecology and Obstetrics. 2001.
19. Gustafsson 1999 Gustafsson J-A. Estrogen receptor beta a new dimension in estrogen mechanism of action. Journal of Endocrinology 1999;163:379-383.
20. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library 2005, issue 3.
21. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
22. Janine 1990 Janine A, Carlos C, Early JE. Raloxifene: A Selective Estrogen Receptor Modulator. American Family Physician 1990;60:1131-9.
23. Jirecek 2004 Jirecek S, Lee A, Pavo I, Crans G, Eppel W, Wenzl R. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertility and Sterility 2004;81(1):132-6.
24. Juni 2001 Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ Journals 2001; 323(7303):42-6.
25. Kjaergard 2001 Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
26. Lethaby 2002 Lethaby A, Vollenhoven B. Fibroids. Clinical Evidence 2002;8:1666-78.
27. Martin 2000 Dutertre M, Smith C. Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action. The Journal of Pharmacology and Experimental Therapeutics 2000;295(2):431-7.
28. Matta 1989 Matta WHM, Shaw RW, Nye M. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. British Journal of Obstetric and Gynaecology 1989;96:200-6.
29. Mitlak 1997 Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Hormone Research 1997;48:155-63.
30. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad A, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis. The Lancet 1998;352:609-13.
31. Otubu 1982 Otubu JA, Buttrum VC, Besch NF, Besch PK. Unconjugated steroids in leiomyomas and tumor-bearing myometrium. American Journal of Obstetric and Gynecology 1982;143:130-3.
32. Palomba 2002 Palomba S, Russo T, Orio F Jr, Tauchmanova L, Zupi E, Panici PL, et al.Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Human Reproduction 2002;17(12):3213-9.
33. Ravina 1995 Ravina JH, Herbreteau D, Ciraru-Vigneron N, Bouret J, Houdart E, Aymard A, et al.Arterial embolisation to treat uterine myomata. The Lancet 1995;346:671-2.
34. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias.Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. The Journal of the American Medical Association 1995;273:408-12.
35. Stewart 1992 Stewart EA, Friedman AJ. Steroidal treatment of myomas: preoperative and long term medical therapy. Seminars in Reproductive Endocrinology 1992;10:344-57.
36. Tamaya 1985 Tamaya T, Fujimoto J, Okada H. Comparison of cellular levels of steroid receptors in uterine leiomyomas and myometrium. Acta Obstetricia et Gynecologica Scandinavica 1985;64:307-9.
37. Vercellini 1993 Vercellini P, Vendola N, Ragni G, Trespidi L, Oldani S, Crosignani PG. Abnormal uterine bleeding associated with iron-deficiency anemia: Etiology and role of hysteroscopy. Journal of Reproductive Medicine 1993;38:502-4.
38. Vollenhoven 1994 Vollenhoven BJ, Pearce P, Herington AC, Healy DL. Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women. Clinical Endocrinology 1994;40(4):537-44.
39. Wilson 1980 Wilson EA, Yang F, Rees ED. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissue. Obstetrics and Gynecology 1980;55:20-4.